Business
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"text","content":"Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the second quarter 2022 Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million NOVATO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended June 30, 2023 and provided its financial guidance for the year. “In the second quarter, our global commercial efforts have resulted in continued meaningful growth of Crysvita, Dojolvi and Mepsevii revenue, including in our key territories outside of the U.S.,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “At the same time, we have continued to advance key clinical programs for osteogenesis imperfecta (OI), Angelman syndrome and Wilson disease, which are expected to generate a number of data catalysts over the next few quarters.” Second Quarter 2023 Selected Financial Data Tables and Financial Results Revenues (dollars in thousands), (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Crysvita Collaboration revenue in profit-share territory$19,799 $51,609 $69,705 $96,773 Royalty revenue 29,061 — 29,061 — Non-cash royalty revenue 17,270 5,423 22,152 10,261 Product sales 16,884 12,402 38,118 21,796 Total Crysvita revenue 83,014 69,434 159,036 128,830 Dojolvi 16,491 13,497 30,794 25,926 Mepsevii 8,439 4,933 16,919 9,794 Evkeeza 365 — 577 — Daiichi Sankyo — 1,479 1,479 4,728 Total revenues$108,309 $89,343 $208,805 $169,278 Total RevenuesUltragenyx reported $108.3 million in total revenue for the second quarter of 2023, which represents 21% growth compared to the second quarter 2022. This includes second quarter 2023 Crysvita revenue in North America of $61.3 million, which represents 19% growth versus the same time period in 2022. The growth in the region continued on its current trajectory while commercialization responsibilities for Crysvita in North America were trans...